Versartis, Inc.: Series B $21M

Posted in I - Series B, Q - 1Q11, R - WEST, X - Endocrinology, X - Growth Deficiency, XX - CA

Versartis (Mountain View, CA) a clinical-stage biopharma company focused on growth hormone deficiency and additional endocrine disorders, closed a $21M Series B financing. Participants include Advent Venture Partners, Index Ventures and Amunix.

Jun

2009

Versartis, Inc.: Series A $11M

Posted in I - Series A, Q - 2Q09, R - WEST, X - Diabetes, X - Endocrinology, X - Growth Deficiency, X - Metabolism, XX - CA

Versartis (Redwood City, CA) a preclinical-stage large molecule company focused on diabetes and growth hormone deficiency, closed an $11M Series A financing. Participants include Index Ventures.

Apr

2009

Ambrx, Inc.: Series D $10M

Posted in I - Series D, Q - 2Q09, R - WEST, X - Antibody, X - Growth Deficiency, X - Multiple Sclerosis, XX - CA

Ambrx (La Jolla, CA) a clinical-stage protein therapeutic company focused growth deficiency, closed a $10M Series D financing. Participants include Merck Serono, 5AM Ventures, Aravis Ventures, CMEA Capital, Maverick Capital, Versant Ventures and Tavistock Life Sciences.

to top of page...